Last updated: September 9, 2026
Novolin 70/30 is a mature human-insulin premix containing 70% NPH insulin and 30% regular human insulin. Its commercial profile is defined by low price, broad clinical familiarity, and declining use relative to insulin analogs such as insulin lispro mix 75/25 and insulin aspart mix 70/30. Novo Nordisk does not report Novolin 70/30 revenue as a standalone product, so its financial trajectory must be inferred from Novo’s insulin portfolio, pricing actions, channel access, and the broader shift toward analog and automated insulin therapy.
The product has limited patent value. Its principal commercial defenses are manufacturing scale, FDA approval history, distribution, payer access, brand recognition, and low cash pricing. Paragraph IV litigation, biosimilar substitution and patent-driven exclusivity loss are not the primary risks. The main risks are substitution by competing premixed analogs, basal-bolus regimens, continuous glucose monitoring, and lower-cost human insulin products.
What is Novolin 70/30 and how does it work?
Novolin 70/30 is a premixed formulation of human insulin designed to provide both mealtime and intermediate-duration insulin coverage. The formulation contains:
| Attribute |
Novolin 70/30 profile |
| Active ingredient |
Recombinant human insulin |
| Composition |
70% NPH insulin, 30% regular human insulin |
| Dosage form |
Injectable suspension |
| Administration |
Subcutaneous injection |
| Main use |
Glycemic control in diabetes mellitus |
| Manufacturer |
Novo Nordisk |
| U.S. regulatory pathway |
FDA-approved insulin product |
| Principal competitors |
Humulin 70/30, insulin lispro mix 75/25, insulin aspart mix 70/30 |
| Commercial position |
Mature, low-cost human-insulin product |
The fixed ratio simplifies dosing but limits flexibility. Patients must coordinate meals and injection timing around the pharmacokinetic profile of regular insulin and NPH insulin. That limitation has reduced the product’s appeal relative to rapid-acting analog premixes and basal-bolus treatment.
What is the FDA regulatory status of Novolin 70/30?
Novolin 70/30 has long-standing FDA approval as a human-insulin product. The product label identifies it as an injectable suspension for subcutaneous use and provides dosing, storage, administration, and safety information for diabetes treatment (U.S. Food and Drug Administration, n.d.-a).
Human insulin products underwent a major regulatory transition in the United States. Under the Biologics Price Competition and Innovation Act framework, insulin products previously approved under the Federal Food, Drug, and Cosmetic Act were transitioned to the Public Health Service Act biologics framework in 2020. This transition made the biosimilar and interchangeable-biologic pathway legally relevant to insulin products, although the practical competitive impact varies by formulation and manufacturer (U.S. Food and Drug Administration, 2020).
Does Novolin 70/30 have FDA exclusivity?
Novolin 70/30 is a mature product and is not protected by meaningful remaining regulatory exclusivity. Any original new-drug exclusivity period expired decades ago. The product’s commercial position therefore depends on manufacturing and distribution rather than FDA exclusivity.
The product’s approval age also means that regulatory exclusivity is not a material constraint on competing human-insulin or premixed-insulin products. A competitor generally would not need to wait for the expiration of a current Novolin 70/30 exclusivity period before entering the market.
What patents protect Novolin 70/30?
The principal insulin molecule and the basic premix concept are mature technologies. Any original composition, formulation, or manufacturing patents associated with Novolin 70/30 are expected to have expired. No current patent estate appears to create a substantial barrier to competing human-insulin premix products.
Potentially relevant intellectual-property categories include:
| Patent category |
Commercial relevance for Novolin 70/30 |
| Human-insulin composition |
Original rights are expired or commercially weak |
| NPH formulation |
Mature technology with limited blocking value |
| 70/30 premix ratio |
Limited scope and limited remaining exclusivity value |
| Vial and pen delivery systems |
May protect specific devices, not the core product |
| Manufacturing processes |
Can create operational know-how but rarely blocks all entry |
| Packaging and labeling |
Limited ability to prevent product competition |
| Combination with monitoring systems |
Generally separate from the Novolin 70/30 product |
The principal residual IP risk is not a core patent blocking generic or biosimilar entry. It is the possibility that a competitor’s specific manufacturing process, delivery device, container, or manufacturing site raises technical or regulatory barriers. Those barriers affect cost and approval execution rather than create long-term market exclusivity.
What is the Orange Book status of Novolin 70/30?
Novolin 70/30 has historically been associated with an FDA-approved application and product listing. The Orange Book records approved drug products and patent information for applicable products, but an old insulin approval should not be treated as evidence of current patent protection.
For commercial diligence, the relevant conclusion is:
- Original approval-based exclusivity is expired.
- No meaningful current patent barrier is evident from the product’s mature status.
- Any current listing should be evaluated at the specific product and application level.
- Device, packaging, or process rights may exist outside the core Orange Book patent position.
Because insulin products transitioned into the biologics framework, the Purple Book and FDA biologics databases are also relevant to competitive analysis. The transition does not create a new period of market exclusivity for an old product.
When does Novolin 70/30 lose exclusivity?
Novolin 70/30 lost its commercially relevant exclusivity long before the current insulin market. There is no identifiable future “loss of exclusivity” event comparable to the expiry of a modern small-molecule blockbuster patent.
The product’s effective exclusivity timeline is:
| Period |
Event |
Commercial effect |
| Original launch period |
FDA approval and market entry |
Establishment of branded human-insulin position |
| 1990s-2000s |
Growth of insulin analogs |
Increasing clinical substitution |
| 2010s |
Wider use of premixed analogs and pens |
Pressure on human premix demand |
| 2020 |
Insulin regulatory transition |
Biosimilar pathway becomes more relevant |
| 2020s |
Affordability programs and price caps |
Lower prices and reduced revenue per unit |
| Current market |
Mature, low-cost product |
Competition based on access and cost |
How does Novolin 70/30 compare with Humulin 70/30?
Humulin 70/30, manufactured by Eli Lilly, is the closest branded direct competitor. Both products use human insulin in a 70% NPH and 30% regular-insulin premix.
| Factor |
Novolin 70/30 |
Humulin 70/30 |
| Manufacturer |
Novo Nordisk |
Eli Lilly |
| Insulin type |
Human insulin |
Human insulin |
| Premix ratio |
70/30 |
70/30 |
| Clinical positioning |
Low-cost human premix |
Low-cost human premix |
| Main differentiation |
Distribution, formulary access, retail pricing |
Distribution, formulary access, retail pricing |
| Patent advantage |
Limited |
Limited |
| Key commercial threat |
Analog substitution and price pressure |
Analog substitution and price pressure |
The products are close substitutes for many patients, but switching is not always frictionless. Prescribers must account for concentration, administration timing, vial or pen presentation, patient education, and insurance coverage. Those factors give established manufacturers a modest retention advantage despite weak patent protection.
What is the competitive landscape for premixed insulin?
The market divides into three principal segments.
Human premixed insulin
Novolin 70/30 and Humulin 70/30 compete mainly on price and availability. These products remain relevant for patients who need affordable insulin and for health systems managing medication costs.
Premixed insulin analogs
Novo Nordisk’s NovoLog Mix 70/30 and Eli Lilly’s Humalog Mix 75/25 provide faster mealtime insulin action. They typically offer greater dosing convenience but carry higher acquisition costs than traditional human premixes, although payer discounts and patient assistance can narrow the difference.
Basal-bolus and automated insulin therapy
Basal insulin combined with rapid-acting mealtime insulin, continuous glucose monitoring, insulin pumps, and automated insulin-delivery systems compete with premixed insulin at the treatment-regimen level. These approaches offer more dosing flexibility and may improve control for selected patients, but they have higher complexity and cost.
The long-term market pressure on Novolin 70/30 comes primarily from this treatment-regimen substitution rather than from a direct generic attack.
What are the financial drivers for Novolin 70/30?
Novo Nordisk does not separately disclose Novolin 70/30 sales, units, gross margin, or operating profit in its annual reports. The product is included within broader insulin and diabetes-care reporting. Product-level revenue exposure therefore cannot be calculated from the company’s public financial statements.
The main financial drivers are:
- Unit volume. Demand depends on the population using human premix rather than analogs or basal-bolus regimens.
- Net price. Retail discounting, government pricing, pharmacy benefit negotiations, and patient affordability programs reduce realized revenue.
- Channel mix. Cash-pay retail channels, Medicaid, Medicare, commercial insurance, hospitals, and international public tenders have different pricing.
- Manufacturing utilization. Mature human insulin can have favorable manufacturing economics at scale, but lower volume can reduce plant efficiency.
- Product presentation. Vials generally support lower pricing than pen presentations, while pens may support greater adherence and higher revenue per patient.
- Geographic mix. Emerging markets and public-sector procurement can sustain volume but usually at lower prices.
- Portfolio substitution. Novo Nordisk may retain the patient through a different insulin product even when Novolin 70/30 loses share.
Novo Nordisk has reported strong overall growth from diabetes and obesity products, but that growth has been concentrated in newer products, particularly GLP-1 therapies and obesity medicines. Mature human-insulin products have a less favorable mix, with volume and price pressure offsetting their role as dependable cash-generating products (Novo Nordisk, 2025).
How do insulin price caps affect Novolin 70/30 revenue?
Affordability initiatives reduce patient out-of-pocket costs but can also reduce net revenue per prescription. Novo Nordisk announced a $35 monthly out-of-pocket cap for eligible U.S. insulin users, while federal policy also limited Medicare insulin cost-sharing to $35 per month under the Inflation Reduction Act (Novo Nordisk, 2024; Centers for Medicare & Medicaid Services, 2024).
The effect is mixed:
- Lower patient cost can protect demand and reduce abandonment.
- Payer rebates and capped prices reduce net sales per unit.
- Lower prices make Novolin 70/30 more competitive with other human insulin products.
- Price compression limits the product’s ability to generate revenue growth.
- Access programs can preserve strategic value even when they reduce reported net price.
For a mature product, affordability policy is more likely to stabilize volume than restore revenue growth.
Are there Paragraph IV challenges or biosimilar threats?
A conventional Paragraph IV challenge is unlikely to be the main entry mechanism because Novolin 70/30 is an old product without a significant remaining patent barrier. Any ANDA-based challenge would be directed at specific listed patents, if any remained relevant, rather than at a broad exclusivity period.
The biosimilar pathway is legally available for insulin products. A competing manufacturer could pursue a biosimilar or interchangeable insulin strategy, but the commercial opportunity depends on:
- Demonstrating comparability to the reference insulin.
- Matching the premix ratio and dosage form.
- Establishing reliable manufacturing capacity.
- Securing pharmacy, payer, and wholesaler access.
- Supporting physician and patient switching.
- Competing against existing low-cost human insulin.
A biosimilar entrant would therefore face a low patent barrier but a meaningful commercial and manufacturing barrier. The likely initial impact would be price pressure and contracting competition rather than immediate displacement of Novo Nordisk.
What patent litigation or settlement agreements affect Novolin 70/30?
No major current patent litigation or settlement agreement is central to the commercial outlook for Novolin 70/30. The product is too mature for a conventional high-value patent-cliff event to drive market behavior.
Potential disputes would more likely involve:
- Manufacturing processes.
- Insulin purification or crystallization.
- Delivery devices.
- Pen components.
- Trade secrets.
- Regulatory data or biosimilar approval issues.
- Product liability and labeling.
These issues can affect individual competitors but do not appear to change the basic market position of Novolin 70/30.
What is the likely financial trajectory for Novolin 70/30?
The most probable trajectory is mature-to-declining revenue, with occasional volume stabilization from affordability programs and emerging-market demand.
| Driver |
Direction |
Expected effect |
| Use of human premixed insulin |
Downward in developed markets |
Lower volume |
| Demand for affordable insulin |
Supportive |
Volume floor |
| U.S. price caps |
Downward for net price |
Lower revenue per unit |
| Analog premix adoption |
Downward |
Substitution |
| Continuous glucose monitoring and pumps |
Downward |
Regimen displacement |
| Emerging-market access |
Supportive |
Volume offset |
| Manufacturing scale |
Supportive |
Margin protection |
| Biosimilar entry |
Downward |
Additional price pressure |
| Novo portfolio switching |
Mixed |
Retains some patient value |
Novolin 70/30 is likely to remain commercially relevant as a low-cost insulin, but it is unlikely to be a material growth engine for Novo Nordisk. Its strategic value is greater than its likely standalone growth profile because it supports access, portfolio completeness, channel relationships, and patient retention.
Key Takeaways
- Novolin 70/30 is a mature human-insulin premix containing 70% NPH and 30% regular insulin.
- Its original regulatory exclusivity and core patent protection have expired.
- The product faces no material patent-cliff event or obvious Paragraph IV threat.
- The main direct competitor is Humulin 70/30; analog premixes are stronger treatment alternatives.
- Novo Nordisk does not disclose standalone Novolin 70/30 revenue.
- The likely financial trajectory is declining or flat revenue, driven by price compression and substitution.
- U.S. affordability caps support access and volume but reduce net pricing.
- Biosimilar competition is legally possible, but manufacturing, regulatory, payer, and distribution barriers remain significant.
- The product’s commercial defenses are scale, supply reliability, retail access, and low price rather than intellectual property.
FAQs
Is Novolin 70/30 a biologic drug?
Yes. Insulin is a biological product. U.S. insulin products approved under the drug framework transitioned to the Public Health Service Act biologics framework in 2020.
Is Novolin 70/30 interchangeable with Humulin 70/30?
They are clinically similar human-insulin premixes, but patients should not switch products without prescriber or pharmacist direction. Device presentation, concentration, administration timing, and patient response must be evaluated.
Is Novolin 70/30 still sold at Walmart?
Novolin products have historically been available through Walmart’s ReliOn insulin program and other retail channels. Availability and pricing vary by presentation, pharmacy, state, payer, and manufacturer program.
Can a biosimilar company launch a 70/30 human-insulin product?
Yes, the biosimilar framework can apply to insulin, but a competitor must still establish product comparability, manufacturing reliability, regulatory approval, payer access, and commercial distribution.
Does Novolin 70/30 have significant investment value as a standalone product?
No standalone investment case can be established from public filings because Novo Nordisk does not separately report the product’s revenue or profit. Its value is best assessed as part of the company’s mature human-insulin portfolio and affordability strategy.
References
- Centers for Medicare & Medicaid Services. (2024). Insulin cost-sharing limits under the Inflation Reduction Act. https://www.cms.gov
- Novo Nordisk. (2024). Novo Nordisk insulin affordability options and savings programs. https://www.novocare.com
- Novo Nordisk. (2025). Annual report 2024. https://www.novonordisk.com/investors/annual-report.html
- U.S. Food and Drug Administration. (2020). Final rule: Definition of the term “biological product”. https://www.federalregister.gov
- U.S. Food and Drug Administration. (n.d.-a). Novolin 70/30 insulin human injection, suspension prescribing information. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
